arrow
S

Satoru Motoyama

Department of Gastroenterological Surgery
H指数:37
被引数:6,966

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adjuvant nivolumab vs placebo in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: First report of comprehensive biomarker analyses from CheckMate 577
2023-06-011
OA
Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648
2022-06-013
OA
ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury
2021-11-2332
OAAI
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Nivolumab在切除的食管或胃食管交界处癌中的辅助治疗

2021-04-011.0K
OA
B38-CAP is a bacteria-derived ACE2-like enzyme that suppresses hypertension and cardiac dysfunction
2020-02-2647
OAAI